ReviewWorld journal of gastrointestinal pathophysiology2014
Treatment of Helicobacter pylori infection: Past, present and future.
Review in World journal of gastrointestinal pathophysiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02959255 (A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin), which is not on this map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Bibliometric and visualisation analyses of gastric ulcer knowledge areas and emerging trends, 2004-2024.Frontiers in medicine · 2025Pooled it
- High-Dose Dual Therapy Versus Bismuth-Containing Quadruple Therapy for the Treatment of Helicobacter pylori Infection: A Systematic Review with Meta-Analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Pooled it
- Trial
- Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.World journal of gastroenterology · 2015Trial
- The effects of probiotics on treatment of Helicobacter pylori eradication in children.Saudi medical journal · 2015Trial
- Acid-Induced Epimerization of Eudesmin to Epieudesmin: Rapid Bactericidal and Antibiofilm Activity AgainstInternational journal of molecular sciences · 2026Article
- The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations.Nature communications · 2025Article
- Current Understanding of Optimal Prevention of Helicobacter pylori-Induced Cancer.Gastroenterology clinics of North America · 2025Review
- Copper enhances tetracycline resistance via the efflux transporter CrdAB-CzcBA inFrontiers in medicine · 2025Article
- Novel Drug Delivery Systems for CombatingArchives of Razi Institute · 2024Review
- Salivary glands - a new site of Helicobacter pylori occurrence.Journal of applied biomedicine · 2024Article
- Current Worldwide Trends in PediatricChildren (Basel, Switzerland) · 2023Review
- Current guidelines forWorld journal of clinical cases · 2022Review
- Antibiotic resistance of Helicobacter pylori isolated from children in Chongqing, China.European journal of pediatrics · 2022Article
- The Challenges of Eradicating PediatricChildren (Basel, Switzerland) · 2022Review
- Zinc carnosine-based modified bismuth quadruple therapyWorld journal of clinical cases · 2022Article
- Effects of Quadruple Therapy Combined with Probiotics onComputational and mathematical methods in medicine · 2022Article
- Diagnostic Challenges ofCanadian journal of gastroenterology & hepatology · 2022Article
- Therapeutic Potential of Sitafloxacin as a New Drug Candidate forAntibiotics (Basel, Switzerland) · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori (H. pylori) is a major human pathogen associated with significant morbidity and mortality. However, after decades of efforts, treatment of H. pylori remains a challenge for physicians, as there is no universally effective regimen. Due to the rising prevalence of antimicrobial resistance, mainly to clarithromycin, efficacy of standard triple therapies has declined to unacceptably low levels in most parts of the world. Novel regimens, specifically experimented to improve the therapeutic outcome against antibiotic-resistant H. pylori strains, are now recommended as first-line empirical treatment options providing high efficacy (reportedly > 90% in intention to treat analysis) even in high clarithromycin resistance settings. These include the bismuth quadruple, concomitant, sequential and hybrid therapies. Due to the rapid development of quinolone resistance, levofloxacin-based regimens should be reserved as second-line/rescue options. Adjunct use of probiotics has been proposed in order to boost eradication rates and decrease occurrence of treatment-related side effects. Molecular testing methods are currently available for the characterization of H. pylori therapeutic susceptibility, including genotypic detection of macrolide resistance and evaluation of the cytochrome P450 2C19 status known to affect the metabolism of proton pump inhibitors. In the future, use of these techniques may allow for culture-free, non-invasive tailoring of therapy for H. pylori infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.